Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialTony Mok, Nelly Cherciu, Yi‐Long Wu et al.|The Lancet|2019Cited by 3.3k
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790MKenneth S. Thress, Geoffrey R. Oxnard, Brian Dougherty et al.|Nature Medicine|2015Cited by 1.5k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung CancerAlexander Drilon, Vivek Subbiah, Geoffrey R. Oxnard et al.|New England Journal of Medicine|2020Cited by 835
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trialsAlexander Drilon, Robert C. Doebele, Salvatore Siena et al.|The Lancet Oncology|2019Cited by 537
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studyLecia V. Sequist, Geoffrey R. Oxnard, Ji‐Youn Han et al.|The Lancet Oncology|2020Cited by 413